BMY Stock Summary and Trading Ideas (Bristol-Myers Squibb Company | NYSE:BMY)

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.

As of October 2, 2026, BMY stock price climbed to $61.15 with 6,942,107 million shares trading.

BMY has a beta of 0.14, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.01 to the broad based SPY ETF.

BMY has a market cap of $124.85 billion. This is considered a Large Cap stock.

Last quarter Bristol-Myers Squibb Company reported $13 billion in Revenue and $2.04 earnings per share. This beat revenue expectation by $1 billion and exceeded earnings estimates by $.43.

In the last 3 years, BMY traded as high as $68.64 and as low as $39.35.

The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, VOO, SCHD, IVV, SPY.

BMY has outperformed the market in the last year with a return of +42.5%, while the SPY ETF gained +16.1%. In the last 3 month period, BMY beat the market returning +6.3%, while SPY returned +3.6%. However, in the most recent 2 weeks BMY has underperformed the stock market by returning -2.0%, while SPY returned +1.0%.

BMY support price is $59.89 and resistance is $61.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.